What is it about?
To analyse the safety and efficacy of pentoxifylline sustained-release (PTX-SR) treatment in patients with early chronic Peyronie's disease (PD).
Photo by Daria Nepriakhina on Unsplash
Why is it important?
Peyronie’s disease (PD) is a localized connective tissue disorder of the tunica albuginea of the penis and surrounding tissue which results in painful erection, penile curvature and erectile dysfunction (ED). The disorder affects 3.2–8.9% of men in their fifth or sixth decades of age. It has been shown that, of affected men, 80% have ED on testing. Although the exact cause of PD remains unknown, increased levels of TGF β1 in plaques of patients with PD was reported.
Read the Original
This page is a summary of: Retraction statement: A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease, BJU International, February 2015, Wiley, DOI: 10.1111/bju.13063.
You can read the full text:
The following have contributed to this page